Militia Long/Short Equity ETF (ORR)

NASDAQ: ORR · Real-Time Price · USD
36.32
+0.01 (0.03%)
Jun 30, 2026, 4:00 PM EDT - Market closed
Assets$353.47M
Expense Ratio10.91%
PE Ration/a
Shares Out9.61M
Dividend (ttm)n/a
Dividend Yieldn/a
Ex-Dividend Daten/a
Payout Frequencyn/a
Payout Ration/a
Volume100,104
Open35.99
Previous Close36.31
Day's Range35.99 - 36.59
52-Week Low28.76
52-Week High39.39
Betan/a
Holdings170
Inception DateJan 15, 2025

About ORR

Fund Home Page

The Militia Long/Short Equity ETF (ORR) is an exchange-traded fund that mostly invests in long/short alternatives. The fund is an actively managed, high turnover, long/short global equity fund. The long side aims to establish positions in companies in Developed Markets outside of the US with strong expected future cash flows ORR was launched on Jan 15, 2025 and is issued by Militia.

Asset Class Alternatives
Category Long-Short Equity
Region North America
Stock Exchange NASDAQ
Ticker Symbol ORR
ETF Provider Militia

Top 10 Holdings

95.94% of assets
NameSymbolWeight
Taiwan Semiconductor Manufacturing Company LimitedTSM15.67%
Hikari Tsushin, Inc.943514.42%
Grupo Mexico SAB de CV Class BGMEXICOB.MX12.74%
Energy Transfer LPET10.25%
Alphabet Inc.GOOG8.20%
Western Midstream Partners, LPWES7.24%
Grupo Aeroportuario del Pacifico SAB de CV ADRG9N.DE7.19%
Grupo Aeroportuario del Centro Norte SAB de CV ADRG7A.DE7.18%
Axos Financial, Inc.AX6.53%
Amazon.com, Inc.AMZN6.53%
View More Holdings

Performance

ORR had a total return of 23.12% in the past year, including dividends. Since the fund's inception, the average annual return has been 26.25%.

News

AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential

Final UPMC Primary Endpoint Report Details Positive Data from Ovarian Cancer Clinical Trial Combining Ampligen, Pembrolizumab and Cisplatin Final UPMC Primary Endpoint Report Details Positive Data fro...

Other symbols: AIM
7 weeks ago - GlobeNewsWire